Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic and erythematous skin lesions. The purpose of this study was to investigate the suppressive effects of anti-inflammatory and Rehmanniae radix pharmacopuncture on the development of AD-like skin lesions in NC/Nga mice. The AD was induced on the mice's back skin by using biostir AD. The experimental groups were divided into three groups, PPI (anti-inflammatory pharmacopuncture), PPII (Rehmanniae radix pharmacopuncture, hydrodistillation extraction) and PPIII (Rehmanniae radix pharmacopuncture, MeOH extraction). All mice were treated using a 1-mL syringe to inject 0.1 mL of pharmacopuncture at right and left acupoints (BL13) on alternate days. In the control group, normal saline was used instead of pharmacopuncture. The following factors were investigated: (1) optical observations made with a handscope and clinical skin scores were evaluated; (2) tissue (general/immune) mast cells and CCR3(+) eosinophils, as well as vascular endothelial growth factor, fibroblast growth factor, and epidermal growth factor immunoreactive changes were evaluated; (3) CD4(+) and CD8(+) cells in the spleen were immunohistochemically examined; and, (4) the serum immunoglobulin (Ig)E level and lymphokines [interleukin (IL)-2, IL-4] were measured. In the PPI and the PPIII groups, the clinical skin score, total number of mast cells, CCR3(+) eosinophils immunoreaction, and total serum IgE, IL-2, and IL-4 levels were lower than the control group. The PPI and the PPIII groups also showed strong immunohistochemical reactions for vascular endothelial growth factor and fibroblast growth factor. The PPI group particularly showed a very strong immunohistochemical reaction for epidermal growth factor. All groups showed strong immune activity for CD8(+). The PPIII group showed strong immunity for both CD4(+) and CD8(+). From the above results, Rehmanniae radix pharmacopuncture (MeOH extraction) and anti-inflammatory pharmacopuncture exerted anti-allergic and anti-inflammatory effects, suggesting that they are promising agents for improving AD-related symptoms.